Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
US Army
Johnson and Johnson
Chubb
Moodys
McKesson
Julphar
Cantor Fitzgerald

Generated: October 22, 2017

DrugPatentWatch Database Preview

Sanofi Aventis Us Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI AVENTIS US, and what generic alternatives to SANOFI AVENTIS US drugs are available?

SANOFI AVENTIS US has one hundred and thirty-six approved drugs.

There are fifty-seven US patents protecting SANOFI AVENTIS US drugs.

There are one thousand and fifty patent family members on SANOFI AVENTIS US drugs in seventy-four countries and one hundred and forty-eight supplementary protection certificates in fifteen countries.

Summary for Applicant: Sanofi Aventis Us

International Patents:1050
US Patents:57
Tradenames:113
Ingredients:93
NDAs:136
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-002Jan 24, 2011OTCYesYes► Subscribe► Subscribe ► Subscribe
Sanofi Aventis Us
LORELCO
probucol
TABLET;ORAL017535-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
HYGROTON
chlorthalidone
TABLET;ORAL012283-003Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
LANTUS SOLOSTAR
insulin glargine recombinant
INJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
NASACORT HFA
triamcinolone acetonide
SPRAY, METERED;NASAL020784-001Apr 7, 2004DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
LASIX
furosemide
SOLUTION;ORAL017688-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA HIVES
fexofenadine hydrochloride
TABLET;ORAL020872-006Jan 24, 2011OTCYesNo► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
SKELID
tiludronate disodium
TABLET;ORAL020707-001Mar 7, 1997DISCNYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
GAVISCON
aluminum hydroxide; magnesium trisilicate
TABLET, CHEWABLE;ORAL018685-001Dec 9, 1983OTCYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
APIDRA
insulin glulisine recombinant
INJECTABLE;IV (INFUSION), SUBCUTANEOUS021629-002Dec 20, 2005RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sanofi Aventis Us

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
BRICANYL
terbutaline sulfate
INJECTABLE;INJECTION017466-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-001Jan 31, 2005► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA HIVES
fexofenadine hydrochloride
TABLET;ORAL020872-008Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373-001Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
LORELCO
probucol
TABLET;ORAL017535-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA HIVES
fexofenadine hydrochloride
TABLET;ORAL020872-008Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-003Nov 17, 2006► Subscribe► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA HIVES
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-003Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
INTAL
cromolyn sodium
CAPSULE;INHALATION016990-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
AVAPRO
irbesartan
TABLET;ORAL020757-001Sep 30, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SANOFI AVENTIS US drugs

Drugname Dosage Strength Tradename Submissiondate
nicotine
Transdermal System7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs
NICODERM CQ
5/30/2014
dronedarone hydrochloride
Tablets400 mg
MULTAQ
7/1/2013
oxaliplatin
Injection5 mg/mL, 40 mL vial
ELOXATIN
3/23/2011
fexofenadine hydrochloride
Oral Suspension30 mg/5 mL
ALLEGRA
1/25/2010
docetaxel
Injection40 mg/mL, 0.5 mL and 2 mL vials
TAXOTERE
6/30/2009
clopidogrel bisulfate
Tablets300 mg
PLAVIX
3/4/2009
oxaliplatin
Injection200 mg/40 mL
ELOXATIN
7/16/2007
oxaliplatin
Injection5 mg/mL, 10 mL and 20 mL vials
ELOXATIN
2/9/2007
oxaliplatin
For Injection50 mg/vial and 100 mg/vial
ELOXATIN
2/9/2007
enoxaparin sodium
Injection100 mg/mL, 3 mL vials
LOVENOX
12/7/2006
irbesartan and hydrochlorothiazide
Tablets300 mg/25 mg
AVALIDE
6/6/2006
zolpidem tartrate
Extended-release Tablets6.25 mg
AMBIEN CR
2/24/2006
zolpidem tartrate
Extended-release Tablets12.5 mg
AMBIEN CR
1/19/2006
irbesartan and hydrochlorothiazide
Tablets150 mg/12.5 mg and 300 mg/12.5 mg
AVALIDE
11/10/2004
irbesartan
Tablets75 mg, 150 mg and 300 mg
AVAPRO
5/25/2004

Premature patent expirations for SANOFI AVENTIS US

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Sanofi Aventis Us

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,905,867Pen-type injector► Subscribe
6,218,553 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor► Subscribe
8,070,727Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,147,870Osmotic device containing pseudoephedrine and an H1 antagonist► Subscribe
6,187,791 Method of providing an antihistaminic effect in a hepatically impaired patient► Subscribe
7,205,276Zinc-free and low-zinc insulin preparations having improved stability► Subscribe
6,100,404 Erythromycin compounds► Subscribe
9,526,843Drive mechanisms suitable for use in drug delivery devices► Subscribe
6,372,780 Methods of treating cell lines expressing multidrug resistance P-glycoprotein► Subscribe
6,046,322 Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sanofi Aventis Us Drugs

Country Document Number Estimated Expiration
Taiwan200507897► Subscribe
Norway20082904► Subscribe
Denmark1603610► Subscribe
Austria303797► Subscribe
South Korea101547880► Subscribe
Slovenia2263724► Subscribe
Spain2321460► Subscribe
Norway179042► Subscribe
Hungary228847► Subscribe
Slovenia680967► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sanofi Aventis Us Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2005 00018Denmark► Subscribe
2107069/02Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
2013010,C1667986Lithuania► SubscribePRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
00596Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001EU/1/12/807/004EU/1/12/807/005EU/1/12/807/007EU/1/12/807/008EU/1/12/807/009EU/1/12/807/012EU/1/12/807/013EU/1/12/807/015 2013210121
/1998Austria► SubscribePRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
00714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
/2005Austria► SubscribePRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 50:50; REGISTRATION NO/DATE: EU/1/00/142/011 - EU/1/00/142/016 20051005
0596Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
366Luxembourg► SubscribePRODUCT NAME: TERIFLUNOMIDE,SON STEREOISOMERE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Colorcon
Farmers Insurance
Dow
Citi
Chubb
Moodys
Fish and Richardson
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot